Bryant Furlow - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Bryant Furlow's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Bryant Furlow
Verified
Public Health Reporter, The Lancet
New Mexico
Beats
Biography
A biologist by training, I work at the crossroads of medical research, public policy, culture and accountability journalism. My reporting over recent years has exposed and explored the off-label sedation of jail inmates with dangerous and addictive drug cocktails, lax state regulation of the health insurance industry, rural ambulance response times following EMS staff cuts, and repeated occupational safety violations in the months leading up to a deadly oil refinery explosion. Lately, I have been exploring health care in Native American communities and implementation of the Affordable Care Act, for New Mexico in Depth. I serve on the board of directors of the Rio Grande Chapter of the Society of Professional Journalists (SPJ-NM) and its Freedom of Information Committee.
Content
By Bryant Furlow Verified| The Lancet Verified These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
By Bryant Furlow Verified| Hematology Advisor Verified The recent wildfires in Los Angeles are just the latest in a series of natural disasters that have disrupted cancer care.1-5 As these disasters become more and more common, experts are recommending that cancer centers and other health care facilities take steps to prevent or reduce disruptions in care and lower risks for patients.
By Bryant Furlow Verified| Hematology Advisor Verified The AlloHeme test can be used to predict relapse after allogeneic hematopoietic cell transplant (HCT) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), according to results from the ACROBAT trial presented at the Tandem Meetings 2025. AlloHeme is a chimerism-monitoring test with a limit of detection of 0.016%, said study presenter Monzr M. Al Malki, MD, of the City of Hope Cancer Center in Duarte, California.
Company Info
The Lancet